Jubilant Ingrevia (JUBLINGREA) Panoramica del titolo
Jubilant Ingrevia Limited si occupa di prodotti e soluzioni per le scienze della vita in India, Stati Uniti, Europa, Cina e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 3/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per JUBLINGREA dai nostri controlli di rischio.
JUBLINGREA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Jubilant Ingrevia Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹746.10 |
| Massimo di 52 settimane | ₹795.00 |
| Minimo di 52 settimane | ₹537.30 |
| Beta | 0.28 |
| Variazione di 1 mese | 8.04% |
| Variazione a 3 mesi | -1.42% |
| Variazione di 1 anno | 4.06% |
| Variazione a 3 anni | 72.29% |
| Variazione a 5 anni | 6.88% |
| Variazione dall'IPO | 177.67% |
Notizie e aggiornamenti recenti
Articolo di analisi • Jul 27
The Jubilant Ingrevia Limited (NSE:JUBLINGREA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest first-quarter results, which makes it a good...
Aggiornamento narrativa • Jul 13
JUBLINGREA: Upcoming Board Decisions May Temper But Sustain Current Optimism
Analysts have raised their price target on Jubilant Ingrevia from ₹657 to ₹705, citing revised assumptions on revenue growth, profit margins, and a lower future P/E multiple in their updated models. What’s in the News for Jubilant Ingrevia Jubilant Ingrevia has scheduled a board meeting on May 26, 2026, at 11:10 Indian Standard Time to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Recent updates
Articolo di analisi • Jul 27
The Jubilant Ingrevia Limited (NSE:JUBLINGREA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest first-quarter results, which makes it a good...Aggiornamento narrativa • Jul 13
JUBLINGREA: Upcoming Board Decisions May Temper But Sustain Current Optimism
Analysts have raised their price target on Jubilant Ingrevia from ₹657 to ₹705, citing revised assumptions on revenue growth, profit margins, and a lower future P/E multiple in their updated models. What’s in the News for Jubilant Ingrevia Jubilant Ingrevia has scheduled a board meeting on May 26, 2026, at 11:10 Indian Standard Time to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Aggiornamento narrativa • Jun 15
JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility
Analysts keep the Jubilant Ingrevia price target steady at ₹1,150, citing only marginal updates to the discount rate, revenue growth, profit margin, and future P/E assumptions that are not large enough to shift their overall view. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 a.m. IST to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Aggiornamento narrativa • Jun 01
JUBLINGREA: Upcoming Board Decisions Will Support Confidence In Long Term Earnings Visibility
Analysts have lifted their price target on Jubilant Ingrevia from ₹1,100 to ₹1,150 as they now apply a higher future P/E multiple, along with slightly lower assumptions for the discount rate, revenue growth and profit margin. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 IST to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Aggiornamento narrativa • May 06
JUBLINGREA: Upcoming Meetings Will Highlight Risks To Current Optimism
Analysts have kept their price target for Jubilant Ingrevia steady at ₹657. Updated assumptions reflect slightly different views on discount rate, revenue growth, profit margin and future P/E to support this unchanged valuation.Aggiornamento narrativa • Apr 21
JUBLINGREA: Upcoming Postal Ballot Will Support Confidence In Long Term Earnings Visibility
Analysts keep the fair value estimate for Jubilant Ingrevia steady at ₹1,100, with only small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News Jubilant Ingrevia has scheduled a Special or Extraordinary Shareholders Meeting for April 4, 2026, to be conducted via postal ballot in India (Key Developments).Aggiornamento narrativa • Apr 07
JUBLINGREA: Upcoming Meetings Will Strengthen Confidence In Long Term Earnings Visibility
Analysts have kept the Jubilant Ingrevia price target unchanged at ₹1,100, with slight tweaks to model inputs such as discount rate, revenue growth, profit margin and future P/E, which underpin the refreshed view. What's in the News Board meeting scheduled for Feb 04, 2026 to consider unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025, which could provide fresh visibility on recent operating trends (Key Developments).Aggiornamento narrativa • Mar 24
JUBLINGREA: Upcoming Board Meeting Will Clarify Bullish Medium Term Outlook
Analysts have maintained the fair value for Jubilant Ingrevia at ₹657. A slightly lower discount rate, marginally higher assumptions for revenue growth and profit margins, and a modestly reduced future P/E expectation together shape the updated price target view.Aggiornamento narrativa • Mar 09
JUBLINGREA: Future Board Decisions Will Support Stronger Long Term Earnings Visibility
Analysts have trimmed their price target on Jubilant Ingrevia from ₹1,250 to ₹1,100. This reflects updated assumptions in their models around slightly softer revenue growth, lower profit margins and a higher future P/E multiple.Aggiornamento narrativa • Feb 23
JUBLINGREA: Upcoming Results And Refined Assumptions Will Shape Medium Term Outlook
Analysts have kept their fair value estimate for Jubilant Ingrevia unchanged at ₹657, while slightly adjusting their assumptions around discount rate, revenue growth, profit margin and future P/E to reflect a more balanced risk and earnings profile. What's in the News Board meeting scheduled on February 4, 2026, to consider the unaudited standalone financial results for the quarter ended December 31, 2025 (company filing).Aggiornamento narrativa • Feb 09
JUBLINGREA: Upcoming Results And Assumption Tweaks Will Shape Medium Term Outlook
Narrative Update The analyst price target for Jubilant Ingrevia has been revised from ₹695 to ₹657 as analysts factor in updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Board meeting scheduled for Feb 04, 2026 to consider Unaudited Standalone Financial Results for the quarter ended Dec 31, 2025 (company filing).Articolo di analisi • Feb 07
Earnings Miss: Jubilant Ingrevia Limited Missed EPS By 17% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) filed its quarterly result this time...Articolo di analisi • Feb 04
Investors Still Waiting For A Pull Back In Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a...Aggiornamento narrativa • Jan 25
JUBLINGREA: Upcoming Board Review And Steady Margins Will Shape Medium Term Outlook
Analysts have maintained their fair value estimate for Jubilant Ingrevia at ₹695.00, making only minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. This reflects a largely unchanged view on the stock's potential.Aggiornamento narrativa • Jan 10
JUBLINGREA: Upcoming Board Review And Margins Will Shape Medium Term Outlook
Analysts have kept their price target for Jubilant Ingrevia steady at ₹695. This reflects only marginal tweaks to assumptions on discount rate, revenue growth, profit margins and expected future P/E rather than a material shift in their overall view.Articolo di analisi • Jan 06
These 4 Measures Indicate That Jubilant Ingrevia (NSE:JUBLINGREA) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Aggiornamento narrativa • Dec 26
JUBLINGREA: Upcoming Results And Margins Will Shape Balanced Medium Term Outlook
Analysts have made a modest upward revision to their price target for Jubilant Ingrevia to ₹695.00, reflecting slightly higher long term valuation multiples despite marginal trims to revenue growth and profit margin assumptions. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value: Unchanged at ₹695.00 per share.Aggiornamento narrativa • Dec 12
JUBLINGREA: Medium Term Margins And Growth Will Shape Fair Outlook
Analysts have reduced their price target for Jubilant Ingrevia to ₹695 from ₹743, reflecting more conservative assumptions on medium-term revenue growth and profit margins, despite a slightly lower discount rate and higher expected future valuation multiples. What's in the News Board meeting scheduled for October 27, 2025, at 13:30 IST to review the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
Aggiornamento narrativa • Nov 27
JUBLINGREA: Solid Revenue Outlook And Profitable Operations Will Boost Future Upside
Analysts have maintained their price target for Jubilant Ingrevia at ₹987.75, citing stable revenue growth prospects and a largely unchanged outlook on profitability and valuation metrics. What's in the News A board meeting is scheduled for October 27, 2025 at 1:30 PM IST to consider the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Aggiornamento narrativa • Nov 13
JUBLINGREA: Strong Profit Margins And Business Outlook Will Drive Share Upside
Analysts have slightly lowered their price target for Jubilant Ingrevia from ₹999.75 to ₹987.75. This change is based on minor adjustments in their valuation models, reflecting updated growth and profitability assumptions.Articolo di analisi • Nov 07
Jubilant Ingrevia (NSE:JUBLINGREA) Shareholders Will Want The ROCE Trajectory To Continue
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Aggiornamento narrativa • Oct 28
Improved Margins And Board Meeting Will Shape Export Opportunity Outlook
The analyst price target for Jubilant Ingrevia has been raised from ₹944.75 to ₹999.75. This reflects an improved margin outlook and a modestly higher profit forecast, according to analysts.Articolo di analisi • Oct 17
Are Investors Undervaluing Jubilant Ingrevia Limited (NSE:JUBLINGREA) By 38%?
Key Insights The projected fair value for Jubilant Ingrevia is ₹1,143 based on 2 Stage Free Cash Flow to Equity...Articolo di analisi • Sep 20
The Price Is Right For Jubilant Ingrevia Limited (NSE:JUBLINGREA)
With a price-to-earnings (or "P/E") ratio of 38.4x Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) may be sending bearish...Articolo di analisi • Jul 03
We Like These Underlying Return On Capital Trends At Jubilant Ingrevia (NSE:JUBLINGREA)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Articolo di analisi • May 16
Jubilant Ingrevia Limited (NSE:JUBLINGREA) Analysts Are Pretty Bullish On The Stock After Recent Results
Last week saw the newest yearly earnings release from Jubilant Ingrevia Limited ( NSE:JUBLINGREA ), an important...Articolo di analisi • Apr 22
Jubilant Ingrevia Limited's (NSE:JUBLINGREA) Share Price Matching Investor Opinion
Jubilant Ingrevia Limited's ( NSE:JUBLINGREA ) price-to-earnings (or "P/E") ratio of 51.7x might make it look like a...
Nuova narrativa • Feb 17
International Expansion And New Vitamin B3 Facility Will Boost Presence In High-Value Products
Specialty Chemicals and Nutrition & Health segments are poised for growth, boosting revenue and margins through high-margin chemicals and vitamin B3 production.Articolo di analisi • Feb 01
Jubilant Ingrevia (NSE:JUBLINGREA) Is Due To Pay A Dividend Of ₹2.50
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) will pay a dividend of ₹2.50 on the 26th of February. Based on this...Articolo di analisi • Jan 31
Results: Jubilant Ingrevia Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week reported its latest quarterly results, which makes it a good...Articolo di analisi • Dec 18
Is Jubilant Ingrevia (NSE:JUBLINGREA) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Sep 11
We Think Jubilant Ingrevia (NSE:JUBLINGREA) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Aug 14
Jubilant Ingrevia (NSE:JUBLINGREA) Is Reinvesting At Lower Rates Of Return
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Articolo di analisi • Jul 19
Jubilant Ingrevia Limited Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) last week released its latest quarterly, and things did...Articolo di analisi • Apr 13
Earnings Tell The Story For Jubilant Ingrevia Limited (NSE:JUBLINGREA) As Its Stock Soars 29%
Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) shares have had a really impressive month, gaining 29% after a shaky...Articolo di analisi • Feb 02
Jubilant Ingrevia Limited Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next
Last week, you might have seen that Jubilant Ingrevia Limited ( NSE:JUBLINGREA ) released its quarterly result to the...Articolo di analisi • Feb 01
A Look At The Fair Value Of Jubilant Ingrevia Limited (NSE:JUBLINGREA)
Key Insights Jubilant Ingrevia's estimated fair value is ₹545 based on 2 Stage Free Cash Flow to Equity With ₹438 share...Articolo di analisi • Oct 19
Returns At Jubilant Ingrevia (NSE:JUBLINGREA) Are On The Way Up
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Rendimenti per gli azionisti
| JUBLINGREA | IN Chemicals | IN Mercato | |
|---|---|---|---|
| 7D | 1.1% | 1.9% | 2.2% |
| 1Y | 4.1% | -1.9% | 3.7% |
Ritorno vs Industria: JUBLINGREA ha superato il Indian Chemicals che ha restituito -1.9 % nell'ultimo anno.
Rendimento vs Mercato: JUBLINGREA ha eguagliato il mercato Indian che ha restituito 3.7 % nell'ultimo anno.
Volatilità dei prezzi
| JUBLINGREA volatility | |
|---|---|
| JUBLINGREA Average Weekly Movement | 4.9% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Prezzo delle azioni stabile: JUBLINGREA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di JUBLINGREA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2019 | 2,185 | Deepak Jain | jubilantingrevia.com |
Jubilant Ingrevia Limited si occupa di prodotti e soluzioni per le scienze della vita in India, Stati Uniti, Europa, Cina e a livello internazionale. Opera in tre segmenti: Specialty Chemicals, Nutrition & Health Solutions e Chemical Intermediates. Il segmento Specialty Chemicals offre biopiridine e picoline, prodotti di chimica fine, prodotti agrochimici, servizi di sviluppo e produzione personalizzati e soluzioni di controllo microbico.
Jubilant Ingrevia Limited Riepilogo dei fondamenti
| JUBLINGREA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹118.50b |
| Utili (TTM) | ₹3.09b |
| Ricavi(TTM) | ₹46.50b |
38.1x
Rapporto P/E2.5x
Rapporto P/SJUBLINGREA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| JUBLINGREA Conto economico (TTM) | |
|---|---|
| Ricavi | ₹46.50b |
| Costo del fatturato | ₹28.60b |
| Profitto lordo | ₹17.90b |
| Altre spese | ₹14.82b |
| Utili | ₹3.09b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Oct 27, 2026
| Utile per azione (EPS) | 19.57 |
| Margine lordo | 38.50% |
| Margine di profitto netto | 6.64% |
| Rapporto debito/patrimonio netto | 25.3% |
Come si è comportato JUBLINGREA nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.7%
Rendimento attuale del dividendo28%
Rapporto di remunerazioneJUBLINGREA paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di JUBLINGREA| Jubilant Ingrevia date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jul 24 2026 |
| Data di pagamento dei dividendi | Sep 25 2026 |
| Giorni fino al dividendo Ex | 13 days |
| Giorni prima della data di pagamento dei dividendi | 50 days |
JUBLINGREA paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di JUBLINGREAAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/05 13:35 |
| Prezzo dell'azione a fine giornata | 2026/08/05 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Jubilant Ingrevia Limited è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Nitesh Dhoot | Anand Rathi Shares and Stock Brokers Limited |
| null null | Asian Markets Securities Private Limited |